{"disease":{"id":"infectious-diarrhea","name":"infectious diarrhea"},"drugs":{"marketed":[{"drug_id":"ciprofloxacine","indication_name":"Infectious diarrheal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Infectious diarrheal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Infectious diarrheal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Infectious diarrheal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ofloxacine","indication_name":"Infectious diarrheal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07342088","title":"Lactobacillus Acidophilus and Limosilactobacillus Reuteri for Acute Diarrhea in Children","phase":"NA","overall_status":"COMPLETED","enrollment_count":145,"lead_sponsor_name":"Eskisehir Osmangazi University","has_results":false},{"nct_id":"NCT05008640","title":"Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™","phase":"","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"Toi Labs, Inc.","has_results":false},{"nct_id":"NCT03809117","title":"Film Array Gastrointestinal Panel Compared to Usual Care for ED Evaluation of Infectious Diarrhea","phase":"NA","overall_status":"TERMINATED","enrollment_count":74,"lead_sponsor_name":"Andrew Meltzer","has_results":true},{"nct_id":"NCT05933525","title":"Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Immuron Ltd.","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}